Back to All Combinations

ALK Fusion

Intermediate Prognosis
0.10% Prevalence Level 3 Rare Fusions
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
ALK
Treatment Implications

Extremely rare. Case reports of responses.

Recommended Treatments
Alectinib
Lorlatinib
Crizotinib
Treatments to Avoid

No specific contraindications noted

Study References

Case reports

Key Statistics
0.10%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Identified incidentally on NGS.
Information

Category: Rare Fusions

Evidence Level: Level 3

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.